Improving patient outcomes with MR-guided daily adapted SABR for prostate cancer
In the treatment of the most common cancer in men, the MRIdian MR-linac has enabled GenesisCare to take prostate cancer radiotherapy to the next level. Dr Killian Nugent shares the results of one of the largest patient reported outcomes studies demonstrating how the innovative technology of the MRIdian MR-linac is improving the accuracy and confidence with which treatment can be delivered to men with localised prostate cancer.
The content on this page is provided by the individuals concerned and does not represent the views or opinions of RAD Magazine.